María
Díez Campelo
Profesora Asociada CC. Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen del Rocío (12)
2022
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436
2020
-
Luspatercept in patients with lower-risk myelodysplastic syndromes
New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151
2019
-
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162
-
The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability
Stem Cells, Vol. 37, Núm. 10, pp. 1357-1368
2017
-
Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study
International Journal of Molecular Sciences, Vol. 18, Núm. 4
2015
-
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Leukemia Research, Vol. 39, Núm. 3, pp. 296-306
-
Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow
Stem Cell Research and Therapy, Vol. 6, Núm. 1
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Uptake and delivery of antigens by mesenchymal stromal cells
Cytotherapy, Vol. 15, Núm. 6, pp. 673-678